#$%^&*AU2016203211C120180301.pdf#####ABSTRACT Use of a pharmaceutical composition in the manufacture of a medicament for treating hematoma expansion or recurrent bleeding resulting from a hemorrhagic condition in brain and for improving patient outcome, the pharmaceutical composition comprising a pharmaceutically acceptable carrier comprising a biodegradable polymer comprising a matrix； wherein the carrier polymer can be formed to produce a solid structure selected from the group consisting of: nonpareils, pellets, strings, sheets, crystals, an agglomerate, microparticles, and nanoparticles, wherein (a) the solid structure contains a therapeutic amount of at least one anti-fibrinolytic agent selected from the group consisting of aminocaproic acid (AMICAR), tranexamic acid, Factor VII, aprotinin, an antiplasmin, fibrin fragment D, a vitamin K, and 4-aminomethylbenzoic acid； (b) the solid structure is dispersed in the matrix, (c) gradual release of the anti-fibrinolytic agent is gradually released over an extended period of time that results in substantially constant blood levels of the anti-fibrinolytic agent over the extended time period into a fluid-filled space or cavity selected from a subarachnoid space a subdural cavity of a chronic SDH, or a cavity left after surgical evacuation of a hematoma, tumor or vascular malformation in the brain, and (d) site-specific activity provides high concentrations of the therapeutic agent at the site where therapeutic activity is needed and lower concentrations in the rest of the body, thus decreasing the risk of unwanted systemic side effects associated with systemic administration of the antifibrinolytic agent.
